Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Hinz, Michael Dr. (1) Janz, Martin Dr. (4) Kammertöns, Thomas Dr. (4) Leisegang, Matthias Prof. Dr. rer. nat. (1) Lusatis, Simone (1) Mathas, Stephan Dr. (6) Pezzutto, Antonio Prof. Dr. (2) Scheidereit, Claus Prof. Dr. (1) Selbach, Matthias Prof. Dr. (5) Uckert, Wolfgang Prof. Dr. (1) Willimsky, Gerald Dr. (3) (-) Blankenstein, Thomas Prof. Dr. (20) (-) Daniel, Peter Prof. Dr. (1) (-) Wollert-Wulf, Brigitte (2) (-) Biologie maligner Lymphome (3) Genetik und Genomik von Herz- Kreislauferkrankungen (1) (-) Molekulare Immunologie und Gentherapie (20) Translationale Onkologie solider Tumore (1) 1992 (4) 1993 (7) 1994 (5) 1995 (8) (-) 1996 (6) 1997 (9) 1998 (9) 1999 (2) (-) 2000 (8) (-) 2001 (5) 2002 (5) 2003 (9) 2004 (8) 2005 (10) (-) 2006 (4) 2007 (5) 2008 (5) 2009 (2) 2010 (7) 2011 (5) 2012 (6) 2013 (13) 2014 (4) 2015 (5) 2016 (4) 2017 (6) 2018 (4) 2019 (6) 2021 (4) 2022 (6) 2023 (6) 2024 (2) 23 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Daniel, Peter Prof. Dr.Wollert-Wulf, BrigitteBiologie maligner LymphomeMolekulare Immunologie und Gentherapie 1996200020012006 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou 01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel 01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken 01. Januar 2001 / Eur J Immunol Decreased generation of anti-tumor immunity after intrasplenic immunization S. Cayeux Z.H. Qin B. Doerken T. Blankenstein 01. Januar 2001 / Nat Med Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay C. Becker H. Pohla B. Frankenberger T. Schueler M. Assenmacher D.J. Schendel T. Blankenstein 03. Dezember 2001 / J Exp Med Tumor rejection by disturbing tumor stroma cell interactions S. Ibe Z.H. Qin T. Schueler S. Preiss T. Blankenstein 17. Dezember 2001 / J Exp Med Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8+ T cells T. Schueler T. Kammertoens S. Preiss P. Debs N. Noben-Trauth T. Blankenstein 01. Februar 2000 / Canc Res Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors G. Willimsky T. Blankenstein 01. Januar 2000 / Hum Gene Ther Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype W. Uckert C. Becker M. Gladow D. Klein T. Kammertoens L. Pedersen T. Blankenstein 01. Juni 2000 / Immunity CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNgamma receptor expression by nonhematopoietic cells Z.H. Qin T. Blankenstein Seitennummerierung Aktuelle Seite 1 Seite 2 Seite 3 Nächste Seite Next › Letzte Seite Last »
15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel
01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
01. Januar 2001 / Eur J Immunol Decreased generation of anti-tumor immunity after intrasplenic immunization S. Cayeux Z.H. Qin B. Doerken T. Blankenstein
01. Januar 2001 / Nat Med Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay C. Becker H. Pohla B. Frankenberger T. Schueler M. Assenmacher D.J. Schendel T. Blankenstein
03. Dezember 2001 / J Exp Med Tumor rejection by disturbing tumor stroma cell interactions S. Ibe Z.H. Qin T. Schueler S. Preiss T. Blankenstein
17. Dezember 2001 / J Exp Med Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8+ T cells T. Schueler T. Kammertoens S. Preiss P. Debs N. Noben-Trauth T. Blankenstein
01. Februar 2000 / Canc Res Interleukin-7/B7.1-encoding adenoviruses induce rejection of transplanted but not nontransplanted tumors G. Willimsky T. Blankenstein
01. Januar 2000 / Hum Gene Ther Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype W. Uckert C. Becker M. Gladow D. Klein T. Kammertoens L. Pedersen T. Blankenstein
01. Juni 2000 / Immunity CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNgamma receptor expression by nonhematopoietic cells Z.H. Qin T. Blankenstein